Elastagen

Elastagen is a clinical stage medical company with an advanced pipeline of products based on the human protein tropoelastin, a pioneering medical biomaterial.

Elastin is a critical component of tissues in the human body which require the ability to stretch and recoil, such as the skin, lungs, arteries, elastic ligaments. Elastagen has developed a synthetic version of the elastin protein which is identical to that naturally present in the human body.

Elastagen’s platform technology has potential applications in a number of areas including skin rejuvenation, scar remodelling and tissue repair.

Elastagen was founded following the acquisition of intellectual property rights to the elastin technology which was developed by Prof Weiss at the University of Sydney. The Company has since successfully attracted capital from a number of leading Australian and overseas life science venture capital groups.

Elastagen’s operations have expanded from its Australian base to include production in Europe and clinical operations in the UK.

Elastagen headquartered in Sydney, New South Wales, Australia, Oceania, operates in the Biotechnology, Medical, Medical Device, Clinical Trials sector. The company focuses on Biotechnology and has secured $725.8M in funding across 48 round(s). With a team of 1-10 employees, Elastagen is actively contributing to advancements in Biotechnology. Their latest funding round, Seed Round - Elastagen, raised $2.0M. Discover more about their projects, partnerships, and impact on our platform.